Recombinant Neisseria meningitidis serogroup C / serotype 2a Quinolinate synthase A(nadA) CSB-EP375490NEX
Specifications
| 20ug / 100ug / 1mg price = 100ug |
Alternative Name(s):
nadA; NMC1772; Quinolinate synthase A; EC 2.5.1.72
Species: (Organism)
Neisseria meningitidis serogroup C / serotype 2a (strain ATCC 700532 / DSM 15464 / FAM18)
Gene Names:
nadA
Tag info:
N-terminal 6xHis-tagged
Target Protein AA Sequence:
MQTAARRSFDYDMPLIQTPTSACQIRQAWAKVADTPDRETAGRLKDEIKALLKEKNAVLVAHYYVDPLIQDLALETGGCVGDSLEMARFGAEHEADTLVVAGVRFMGESAKILCPEKTVLMPDLEAECSLDLGCPEEAFSAFCDQHPDRTVVVYANTSAAVKARADWVVTSSVALEIVSYLKSRGEKLIWGPDRHLGDYICRETGADMLLWQGSCIVHNEFKGQELAALKAEHPDAVVLVHPESPQSVIELGDVVGSTSKLLKAAVSRPEKKFIVATDLGILHEMQKQAPDKEFIAAPTAGNGGSCKSCAFCPWMAMNSLGGIKYALTSGRNEILLDRKLGEAAKLPLQRMLDFAAGLKRGDVFNGMGPA
Expression Region:
1-370aa
Subcellular Location:
Cytoplasm
Tissue Specificity:
Protein Length:
Full Length
Pathway:
Mol. Weight:
44.1 kDa
Purity:
Greater than 85% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Others
Function:
Catalyzes the condensation of iminoaspartate with dihydroxyacetone phosphate to form quinolinate.
Involvement in disease:
Relevance:
Catalyzes the condensation of iminoaspartate with dihydroxyacetone phosphate to form quinolinate.
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
Quinolinate synthase A family, Type 1 subfamily
Reference:
"Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18." Bentley S.D., Vernikos G.S., Snyder L.A.S., Churcher C., Arrowsmith C., Chillingworth T., Cronin A., Davis P.H., Holroyd N.E., Jagels K., Maddison M., Moule S., Rabbinowitsch E., Sharp S., Unwin L., Whitehead S., Quail M.A., Achtman M. Parkhill J. PLoS Genet. 3:230-240(2007)
